Annalisa Massari - Search Results

Year	Number of Results
2012	1
2013	2
2015	1
2020	1
2021	1
2023	2
2024	1

1

Neuroglobin: A New Possible Marker of Estrogen-Responsive Breast Cancer.

Solar Fernandez V, Fiocchetti M, Cipolletti M, Segatto M, Cercola P, Massari A, Ghinassi S, Cavaliere F, Marino M. Solar Fernandez V, et al. Among authors: massari a. Cells. 2021 Aug 5;10(8):1986. doi: 10.3390/cells10081986. Cells. 2021. PMID: 34440755 Free PMC article.

2

Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study.

Nelli F, Fabbri A, Botticelli A, Giannarelli D, Marrucci E, Fiore C, Virtuoso A, Berrios JRG, Scagnoli S, Pisegna S, Cirillo A, Panichi V, Massari A, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: massari a. Front Oncol. 2023 Nov 7;13:1280416. doi: 10.3389/fonc.2023.1280416. eCollection 2023. Front Oncol. 2023. PMID: 38023235 Free PMC article.

3

PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian survey.

Cerbelli B, Cirillo A, Pomati G, Pernazza A, Ascione A, Pisegna S, Pisano A, Leopizzi M, Pignataro MG, Costarelli L, Mulè A, Vecchione A, Catalano P, Coppola L, Perrone G, Perracchio L, Anemona L, Mastracchio A, Nardi S, Reitano R, Massari A, Grillo LR, Liberati F, Della Rocca C, Marchetti P, Botticelli A, D'Amati G. Cerbelli B, et al. Among authors: massari a. Tumori. 2024 Feb;110(1):44-48. doi: 10.1177/03008916231196781. Epub 2023 Sep 19. Tumori. 2024. PMID: 37726962

4

Extracellular Neuroglobin as a Stress-Induced Factor Activating Pre-Adaptation Mechanisms against Oxidative Stress and Chemotherapy-Induced Cell Death in Breast Cancer.

Fiocchetti M, Solar Fernandez V, Segatto M, Leone S, Cercola P, Massari A, Cavaliere F, Marino M. Fiocchetti M, et al. Among authors: massari a. Cancers (Basel). 2020 Aug 29;12(9):2451. doi: 10.3390/cancers12092451. Cancers (Basel). 2020. PMID: 32872414 Free PMC article.

5

Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?

Moscetti L, Agnese Fabbri M, Sperduti I, Fabrizio N, Frittelli P, Massari A, Pompei L, D'Auria G, Pofi E, Ruggeri EM. Moscetti L, et al. Among authors: massari a. Tumori. 2015 Sep-Oct;101(5):469-73. doi: 10.5301/tj.5000376. Epub 2015 Jun 13. Tumori. 2015. PMID: 26108239

6

Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes.

Nelli F, Moscetti L, Natoli G, Massari A, D'Auria G, Chilelli M, Fabbri MA, Frittelli P, Ruggeri EM. Nelli F, et al. Among authors: massari a. Int J Clin Oncol. 2013 Apr;18(2):343-9. doi: 10.1007/s10147-012-0384-x. Epub 2012 Feb 17. Int J Clin Oncol. 2013. PMID: 22350024

7

Epirubicin and docetaxel as first-line treatment for hormonal receptor positive metastatic breast cancer: the predictive value of luminal subtype: a retrospective cohort analysis.

Nelli F, Natoli G, Moscetti L, Massari A, D'Auria G, Fabbri MA, Frittelli P, Ruggeri EM. Nelli F, et al. Among authors: massari a. J Chemother. 2013 Apr;25(2):112-8. doi: 10.1179/1973947812Y.0000000059. J Chemother. 2013. PMID: 23684359

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

7 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year